The Safety and Pharmacokinetics of ASKC200 in Osteoarthritic Knee Pain
Status:
NOT_YET_RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind clinical trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASKC200 in subjects with OA of the knees and determine the phase II recommended dose. Assigned doses will be applied for 60 minutes on each of four consecutive days.